BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BTC Health — Shareholder Meeting (November 2009)
22 slides from BTC Health Ltd Registered's shareholder meeting presentation, Nov 17, 2009
Slide 1: 2009 Annual General Meeting
For personal use only 2009 Annual General Meeting 17 November 2009, Sydney 1
Slide 2: Outline
For personal use only Outline Year in Review Performance Charts Portfolio Highlights and Updates Outlook Background Information 2
Slide 3: Year in Review – Macro
For personal use only Year in Review – Macro Capital markets extended deep losses in the first half of the financial year with many shares hitting deep lows Performance in 2009 marked a return to strong sentiment and significant rallies across the board Australia seems to have out-run deep recession
Slide 4: Year in Review – Macro
For personal use only Year in Review – Macro In addition to strong performances at blue-chip end, investors poured back into speculative stocks in resources as well as life-sciences Many life-science companies have experienced strong re- ratings as investors recognised they had been oversold Stocks
Slide 5: Year in Review - Operating
For personal use only Year in Review - Operating The Board of BTC recognise that the life-science sector remains a highly cyclical and highly volatile sector. Generating returns from early stage investing is extremely long-term and requires considerable follow-on funding to protect initial investmen
Slide 6: Year in Review - Operating
For personal use only Year in Review - Operating Current strength in the Australian life-science market, where many stocks are multiples above their low points of a few months ago, provides a window to seek exits The on-market share buyback remains in place with a goal of keeping the share price as
Slide 7: Relative Performance of BTC vs NASDAQ Biotech Index Since Listing
For personal use only Performance Charts Relative Performance of BTC vs NASDAQ Biotech Index Since Listing 120 100 80 60 40 20 BTC NASDAQ Biotech Index 0 Aug 00 Aug 01 Aug 02 Aug 03 Aug 04 Aug 05 Aug 06 Aug 07 Aug 08 Aug 09 7
Slide 8: Performance Charts
For personal use only Performance Charts 8
Slide 9: Portfolio companies
For personal use only Portfolio companies 9
Slide 10: BTC Portfolio (at market Oct 2009)
For personal use only BTC Portfolio (at market 31 Oct 2009) 1 2 31 October 09 Cost Price Board Valuation Market Valuation Cents per BTC Current Cents per BTC Company ASX Code Cost Price Current Value* Cents per BTC share share Value* share LISTED SECURITIES 1 Alchemia ACL $ 870,299 1.08c $ 862,086 1
Slide 11: Portfolio Highlights and Updates
For personal use only Portfolio Highlights and Updates Alchemia lodges drug master file and subsequently lodges ANDA with US-FDA positioning the company for final regulatory approvals for its synthetic heparin before end of 2009 calendar year. IND filed for its anti-cancer platform combining proprie
Slide 12: Portfolio Highlights and Updates
For personal use only Portfolio Highlights and Updates Generic Health has acquired Max Pharmaceuticals opening a path to the hospital generic market. Revenues continue to grow strongly and the pipeline of new product launches remains solid. Relationship with major shareholder Lupin Ltd of India very
Slide 13: Portfolio Highlights and Updates
For personal use only Portfolio Highlights and Updates Phylogica has now generated a compelling data pack which has led to high level and on-going engagement with major pharmaceutical and biotechnology companies. Demand for use of phylomers in a range of functions including molecular probes, carrier
Slide 14: Portfolio Highlights and Updates
For personal use only Portfolio Highlights and Updates Starpharma has achieved numerous milestones across a range of activities including: A successful $7.1m capital raising; Establishing a partnership with Elanco – the animal health unit of Eli Lilly & Co; Growing licensing revenues from the compan
Slide 15: Outlook
For personal use only Outlook Capital market sentiment currently positive IPO window may re-open in coming months for smaller companies. BTC will focus on every opportunity to exit existing investments Unlisted investments will be reviewed and all avenues will be examined to achieve exits at fair va
Slide 16: Background Information
For personal use only Background Information 16
Slide 17: Our Portfolio
For personal use only Our Portfolio Alchemia – proprietary chemistry technology to produce novel therapeutics Biocomm – holding company to several early stage companies (Cryptopharma, CNS Bio, Hatchtech) Continence Control Systems – developing a portfolio of continence management technologies Generi
Slide 18: Our Portfolio
For personal use only Our Portfolio Phylogica – peptide-based therapeutics Sensear – novel hearing technologies Starpharma – nanotech leader exploiting dendrimer technology platform Stem Cell Sciences – regenerative medicine, drug screening and therapeutics XRT- high resolution imaging techniques 18
Slide 19: Pooled Development Fund Status
For personal use only Pooled Development Fund Status BTC has since inception been registered as a PDF Provides investors certain tax benefits Imposes several investment restrictions on the fund Seeking approval to provide Board discretion to de- register as a PDF if in the best interests of sharehol
Slide 20: Pooled Development Fund Status
For personal use only Pooled Development Fund Status Other issues to consider include: Existing investments will not be impacted Certain tax benefits under the PDF Act will no longer be available to the Fund or to shareholders The Board is seeking discretion in the timing of relinquishing PDF status
Slide 21: Capital Structure
For personal use only Capital Structure Ordinary shares (BTC): 80,664,611 Substantial shareholders (as at 21 September 2009): Select Asset Management: 27.53% Lazard Asset Management: 8.20% Top 20 hold 46.53% 3,772 shareholders 21
Slide 22: Portfolio companies
For personal use only Portfolio companies 22